Compare NUE & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUE | IQV |
|---|---|---|
| Founded | 1905 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8B | 41.3B |
| IPO Year | N/A | 2013 |
| Metric | NUE | IQV |
|---|---|---|
| Price | $179.40 | $164.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 15 |
| Target Price | $175.67 | ★ $236.33 |
| AVG Volume (30 Days) | 2.0M | ★ 2.5M |
| Earning Date | 01-26-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | 7.52 | ★ 7.84 |
| Revenue | ★ $32,494,000,000.00 | $16,310,000,000.00 |
| Revenue This Year | $11.06 | $5.71 |
| Revenue Next Year | $4.73 | $5.77 |
| P/E Ratio | $24.37 | ★ $21.29 |
| Revenue Growth | 5.73 | ★ 5.88 |
| 52 Week Low | $97.59 | $134.65 |
| 52 Week High | $196.90 | $247.05 |
| Indicator | NUE | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 20.65 |
| Support Level | $177.06 | $156.67 |
| Resistance Level | $196.90 | $172.52 |
| Average True Range (ATR) | 5.46 | 10.66 |
| MACD | -0.88 | -5.77 |
| Stochastic Oscillator | 37.17 | 8.07 |
Nucor Corp manufactures steel and steel products. The company's reportable segments are steel mills, steel products, and raw materials. A majority of its revenue is derived from the steel mills segment, which is engaged in producing sheet steel (hot-rolled, cold-rolled, and galvanized), plate steel, structural steel (wide-flange beams, beam blanks, H-piling, and sheet piling), and bar steel products. Nucor manufactures steel principally from scrap steel and scrap steel substitutes using electric arc furnaces (EAFs) along with continuous casting and automated rolling mills. The steel mills segment sells its products mainly to steel service centers, fabricators, and manufacturers located in the United States, Canada, and Mexico.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.